Jefferies Maintains Bullish View on Array BioPharma (ARRY) Following Update from Society for Melanoma Research

Array Biopharma (ARRY), Pierre Fabre Announce Presentation of Binimetinib Combo Phase 3 Data in BRAF-Mutant Melanoma

Array BioPharma (Nasdaq: ARRY) and Pierre Fabre jointly announced new results from the pivotal Phase 3 COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in BRAF-mutant melanoma patients at the Society for Melanoma Research Annual Congress. The study met its primary endpoint, with the combination... More